Skip to content

Ascendis Pharma files for late-stage study with TransCon in Japan

September 23, 2020

Ascendis Pharma (NASDAQ:ASND) has filed a Clinical Trial Notification with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan seeking approval to initiate Phase 3 riGHt Trial of TransCon hGH (lonapegsomatropin), a long-acting prodrug of somatropin (hGH), for the treatment for pediatric growth hormone deficiency (GHD).

The 40-subject trial will evaluate and compare the annualized height velocity in prepubertal treatment naïve children with GHD, treated with weekly TransCon hGH to that of a commercially available daily hGH formulation, at 52 weeks.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: